[{"address1": "275 Wyman Street", "address2": "3rd Floor", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "617 945 5576", "website": "https://www.cogentbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 164, "companyOfficers": [{"maxAge": 1, "name": "Mr. Andrew R. Robbins M.B.A.", "age": 47, "title": "President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 1062957, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John Edward Robinson Ph.D.", "age": 48, "title": "Chief Scientific Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 749895, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jessica  Sachs M.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 773925, "exercisedValue": 0, "unexercisedValue": 418777}, {"maxAge": 1, "name": "Mr. John L. Green C.A., CPA", "age": 43, "title": "CFO & Principal Accounting Officer", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 763987, "exercisedValue": 0, "unexercisedValue": 266409}, {"maxAge": 1, "name": "Mr. Brad  Barnett", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christi  Waarich", "title": "Senior Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Evan D. Kearns J.D.", "age": 43, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin  Schellhammer", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dana R. Martin Pharm.D.", "title": "Senior VP of Medical Affairs & Chief Patient Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Brad  Fell", "title": "Senior Vice President of Chemistry", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 9, "overallRisk": 7, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.48, "open": 11.6, "dayLow": 10.87, "dayHigh": 11.66, "regularMarketPreviousClose": 11.48, "regularMarketOpen": 11.6, "regularMarketDayLow": 10.87, "regularMarketDayHigh": 11.66, "beta": 0.03, "forwardPE": -4.8869567, "volume": 1008535, "regularMarketVolume": 1008535, "averageVolume": 1020340, "averageVolume10days": 997320, "averageDailyVolume10Day": 997320, "bid": 11.19, "ask": 11.26, "bidSize": 400, "askSize": 600, "marketCap": 1230217984, "fiftyTwoWeekLow": 3.67, "fiftyTwoWeekHigh": 12.65, "fiftyDayAverage": 9.2524, "twoHundredDayAverage": 7.395075, "currency": "USD", "enterpriseValue": 1025579328, "floatShares": 70231079, "sharesOutstanding": 109450000, "sharesShort": 10230915, "sharesShortPriorMonth": 10388106, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0935, "heldPercentInsiders": 0.00125, "heldPercentInstitutions": 1.12375, "shortRatio": 16.2, "shortPercentOfFloat": 0.1035, "bookValue": 2.37, "priceToBook": 4.742616, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -227044992, "trailingEps": -2.49, "forwardEps": -2.3, "lastSplitFactor": "1:4", "lastSplitDate": 1604880000, "enterpriseToEbitda": -4.234, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "COGT", "underlyingSymbol": "COGT", "shortName": "Cogent Biosciences, Inc.", "longName": "Cogent Biosciences, Inc.", "firstTradeDateEpochUtc": 1522330200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3a4634b7-b227-3bef-b8b4-12fa6851bf14", "gmtOffSetMilliseconds": -14400000, "currentPrice": 11.24, "targetHighPrice": 22.0, "targetLowPrice": 10.0, "targetMeanPrice": 16.2, "targetMedianPrice": 16.5, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 363216000, "totalCashPerShare": 3.319, "ebitda": -242215008, "totalDebt": 18184000, "quickRatio": 9.08, "currentRatio": 9.249, "debtToEquity": 4.872, "returnOnAssets": -0.37182, "returnOnEquity": -0.62924, "freeCashflow": -100407376, "operatingCashflow": -177271008, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]